The health insurer’s quarterly profit was better than expected; however, Cigna’s revenue and earnings forecast was below Wall Street estimates for its first full year running Express Scripts, according to Reuters.
Cigna also faced headwinds from HHS’ new rule, under which drug manufacturers would no longer be able to give rebates to pharmacy benefit managers, but they would be allowed to offer discounted prices directly to consumers. While Cigna CEO David Cordani said during the health insurer’s fourth quarter earnings call that HHS’ “proposed rebate rule won’t have a meaningful impact on our growth or earnings trajectory,” Barron’s said the rule could chip away profits for Cigna.
“Whatever the outcome of this latest HHS proposal, the risk of federal interference in drug pricing will be with Cigna investors for the foreseeable future,” according to Barron’s.
More articles on payers:
Payer-provider partnerships and market trends
9 ‘Best in KLAS’ value-based care consultants
Companies like LexisNexis are selling patient ‘risk scores’ to hospitals, insurers
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.